An Open-Label, Phase 1, First-In-Human, Dose Escalation And Expansion Study To Evaluate The Safety, Tolerability, Maximum Tolerated Or Administered Dose, Pharmacokinetics, Pharmacodynamics And Tumor Response Profile Of The ILDR2 Function-Blocking Antibody BAY 1905254 In Patients With Advanced Solid Tumors (18789)